Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

Exclusion Criteria

• •Pregnancy \< 16 weeks
• •Microscopically confirmed P. falciparum or mixed infection/ parasitemia (P. vivax and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)
• •History of allergy or hypersensitivity to interventional drugs
• •Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA)
• •Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin)
• •History or family history of epilepsy or psychiatric disorder
• •Presence of signs and symptoms of severe malaria, severe illness, or danger signs
• •Hemoglobin \< 7 g/dl
• •Inability to tolerate oral medication (repeated vomiting, impairment of consciousness).
• •History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV/ AIDS, known hemoglobinopathy
• •Participant's inability to return for follow up visits
• •Age \<15 years